title: Dietary short-chain fructooligosaccharides increase calbindin-D9k levels only in the large intestine in rats independent of dietary calcium deficiency or serum 1,25 dihydroxy vitamin D levels.
abstract: Dietary short-chain fructooligosaccharides (Sc-FOS) increase mucosal calbindin-D9k (CaBP) levels in the large intestine whereas levels in the small intestine are decreased in rats. In the present study, we investigated the mechanism by which Sc-FOS induce this increase in CaBP in the large intestine by measuring intestinal CaBP levels in rats fed normal and calcium-deficient diets. Dietary groups included a calcium-containing (0.5%) diet with or without Sc-FOS (100 g/kg diet) and a calcium-deficient (abt. 0.01%) diet with or without Sc-FOS (100 g/kg diet). The rats were fed these diets for 10 days following which they were killed and the intestine removed for collection of the entire mucosa which was divided into four segments, i.e., proximal and distal segments of the small intestine, the cecum and the colorectum. Mucosal CaBP and plasma calcium (Ca), 1,25-dihydroxycholecalciferol (1,25(OH)2D3), 25-hydroxycholecalciferol (25(OH)D3), parathyroid hormone (PTH) and calcitonin levels were measured. Feeding of calcium deficient diet resulted in an increase in CaBP levels in the small intestine, but did not influence levels in the large intestine. Moreover, a significant positive correlation between plasma 1,25(OH)2D3 and CaBP levels in the case of both small intestinal segments (proximal, r = 0.77012, p < 0.00007; distal, r = 0.75056, p < 0.00014) was observed, but not in the case of the large intestinal segments. Sc-FOS increased CaBP levels in the large intestine. These results suggest that the large intestinal CaBP levels do not change in response to dietary calcium conditions and are not regulated by circulating 1,25(OH)2D3 indicating that the effect of Sc-FOS on CaBP levels in the large intestine is independent of the action of 1,25(OH)2D3.
authors.affiliation: Nutritional Science Center, Meiji Seika Kaisha Ltd., Saitama, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takasaki
authors.forename: H
authors.initials: H
authors.lastname: Inaba
authors.forename: A
authors.initials: A
authors.lastname: Ohta
authors.forename: Y
authors.initials: Y
authors.lastname: Motohashi
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Morris
authors.forename: K
authors.initials: K
authors.lastname: Sakuma
mesh_terms: D000818:Animals; D015153:Blotting, Western; D064026:Calbindins; D002118:Calcium / Q000172:deficiency; D002136:Calcium, Dietary / Q000008:administration & dosage; D007413:Intestinal Mucosa / Q000378:metabolism*; D007420:Intestine, Large / Q000378:metabolism*; D008297:Male; D009844:Oligosaccharides / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D064030:S100 Calcium Binding Protein G / Q000378:metabolism / Q000493:pharmacokinetics*; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000097:blood
chemical_list: D064026:Calbindins; D002136:Calcium, Dietary; D009844:Oligosaccharides; D064030:S100 Calcium Binding Protein G; C576508:S100g protein, rat; C116580:fructooligosaccharide; D014807:Vitamin D; C097949:1,25-dihydroxyvitamin D; D002118:Calcium